Trial Profile

The study of Triprilimab therapy with cytokine induced killer cells in advanced non-small cell lung cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 23 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Antineoplastics (Primary) ; Cytokine-induced killer cell therapy (Primary) ; Toripalimab (Primary)
Indications Non-small cell lung cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Shanghai Junshi Biosciences

Most Recent Events

18 Jun 2025 Results assessing the efficacy and safety of autologous cytokine-induced killer (CIK) cell therapy combined with the anti-PD-1 antibody toripalimab, with or without chemotherapy, as a first-line treatment for advanced NSCLC published in the International Journal of Cancer
18 Jun 2025 Status changed from recruiting to active, no longer recruiting.
06 Jan 2025 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com